Skip to main content

Table 4 Number of annual cases of each lesion attributable to HPV genotypes targeted by the 4-valent and 9-valent vaccines and associated costs

From: Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine

Lesion Cases attributable to HPV 6/11/16/18 and associated costs Cases attributable to HPV 6/11/16/18/31/33/45/52/58 and associated costs Cases attributable to HPV 31/33/45/52/58 and associated costs (a)
Number of annual cases Costs (€ 2017) Number of annual cases Costs (€ 2017) Number of annual cases Costs (€ 2017)
Genital warts (b) 49,251 51.04 Mill € 49,251 51.04 Mill € 0 0.00 Mill €
CIN 2/3 15,285 35.50 Mill € 27,648 64.22 Mill € 12,363 28.72 Mill €
VIN2/3 1001 3.93 Mill € 1162 4.56 Mill € 161 0.63 Mill €
VaIN 2/3 155 0.55 Mill € 186 0.66 Mill € 31 0.11 Mill €
AIN 2/3 (b) 149 0.59 Mill € 162 0.65 Mill € 13 0.05 Mill €
PIN 2/3 218 0.59 Mill € 247 0.67 Mill € 29 0.08 Mill €
Cervical cancer (c) 1730 15.15 Mill € 2110 18.48 Mill € 380 3.33 Mill €
Vulvar cancer (d) 94 1.22 Mill € 110 1.43 Mill € 16 0.21 Mill €
Vaginal cancer (c) 50 0.54 Mill € 66 0.71 Mill € 16 0.17 Mill €
Anal cancer (b)(c)(e) 264 2.02 Mill € 289 2.21 Mill € 25 0.19 Mill €
Penile cancer (c)(e) 98 0.70 Mill € 111 0.79 Mill € 13 0.09 Mill €
Oral cavity (b)(c)(e) 131 1.03 Mill € 147 1.15 Mill € 16 0.12 Mill €
Nasopharynx (b)(c)(e) 27 0.21 Mill € 32 0.25 Mill € 5 0.04 Mill €
Oropharynx cancer (b)(c)(e) 258 1.94 Mill € 272 2.05 Mill € 14 0.10 Mill €
Hypopharynx (b)(c)(e) 28 0.23 Mill € 34 0.28 Mill € 6 0.05 Mill €
Pharynx cancer (b)(c)(e) 39 0.30 Mill € 39 0.30 Mill € 0 0.00 Mill €
Larynx cancer (b)(c)(e) 132 1.15 Mill € 171 1.49 Mill € 39 0.34 Mill €
TOTAL 68,910 116.7 Mill € 82,038 150.9 Mill € 13,128 34.24 Mill €
  1. (a) Difference between the number of cases of each lesion attributable to the genotypes targeted by the 9-valent and 4-valent vaccines and associated costs
  2. (b) Includes both men and women
  3. (c) Genotypes 6 and 11 not included
  4. (d) HPV attributable fraction estimated on HPV DNA and p16 positivity
  5. (e) Only hospitalization costs were considered
  6. AIN anal intraepithelial neoplasia; CIN cervical intraepithelial neoplasia; HPV human papillomavirus; mill.: million; PIN penile intraepithelial neoplasia; VaIN vaginal intraepithelial neoplasia; VIN vulvar intraepithelial neoplasia